共 78 条
[1]
Simonneau G(2019)Haemodynamic definitions and updated clinical classification of pulmonary hypertension Eur Respir J 53 1801913-1256
[2]
Montani D(2012)Mortality in adults with sickle cell disease and pulmonary hypertension JAMA 307 1254-53
[3]
Celermajer DS(2011)A hemodynamic study of pulmonary hypertension in sickle cell disease N Engl J Med 365 44-1324
[4]
Denton CP(2016)Chronic pulmonary complications of sickle cell disease Chest 149 1313-828
[5]
Gatzoulis MA(2016)Pathophysiology and treatment of pulmonary hypertension in sickle cell disease Blood 127 820-740
[6]
Krowka M(2014)An official american thoracic society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease Am J Respir Crit Care Med 189 727-516
[7]
Mehari A(2005)Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension Thromb Haemost 93 512-847
[8]
Gladwin MT(2013)Hemodynamic predictors of mortality in adults with sickle cell disease Am J Respir Crit Care Med 187 840-35
[9]
Tian X(2010)Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies Br J Haematol 149 426-64
[10]
Machado RF(2011)Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity Blood 118 855-e165